COMP <GO>
PAYX vs TMO // EV/EBITDA & P/E VALUATION
Paychex Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: PAYX 8
— TMO 4
▲ EV/EBITDA & P/E VALUATION LEADER: PAYX
LAST: $109.37 (+1.07%) • MKT CAP: $38.93B
valuation
15.5x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAYX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAYX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.60% | 9.30% | +19.30 | PAYX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 15.5x | 30.4x | -14.90 | PAYX | /valuation <GO> |
| Free Cash Flow Yield | 5.96% | 2.40% | +3.56 | PAYX | /fcf-yield <GO> |
| Operating Margin | 39.80% | 17.40% | +22.40 | PAYX | /operating-margins <GO> |
| Net Profit Margin | 27.90% | 15.10% | +12.80 | PAYX | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 3.90% | +12.60 | PAYX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.08% | 0.24% | +3.84 | PAYX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.03 | 4.50 | -1.47 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.2 | 62.9 | -14.70 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.92 | 0.94 | -0.02 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.6x | 36.3x | -17.70 | PAYX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $38.93B | $262.22B | -$223.28B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAYX REV | TMO REV | PAYX GROSS % | TMO GROSS % | PAYX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.30B | $44.56B | 73.4% | — | $2.32B | $6.29B |
| FY 2024 | $5.41B | $42.88B | 71.5% | — | $1.71B | $7.27B |
| FY 2023 | $5.13B | $42.86B | — | — | $1.67B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAYX // BETA 0.92
TMO // BETA 0.94